Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

BACKGROUND: Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden for patien...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Trials
Egile Nagusiak: Michielsens, Celia A. J., Boers, Nadine, den Broeder, Nathan, Wenink, Mark H., van der Maas, Aatke, Mahler, Elien A. M., Mulder, Michelle L. M., van der Heijde, Désirée, van den Hoogen, Frank H. J., Verhoef, Lise M., den Broeder, Alfons A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Study Protocol
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964104/
https://ncbi.nlm.nih.gov/pubmed/31941544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-4000-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak